The Life Sciences Capital Markets team advised Fusion Pharmaceuticals Inc. on its initial public offering of 12,500,000 common shares at a public offering price of $17.00. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Fusion, are expected to be $212.5 million. In addition, Fusion has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 common shares at the initial public offering price.
The shares began trading on the Nasdaq Global Market on June 26, 2020 under the ticker symbol “FUSN”.
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.
The Goodwin team was led by Mitch Bloom, Seo Salimi, Marishka DeToy, Andrew Whitworth and Peter Rodas, and included Julie Tibbets, Alexander Varond, Nikhil Sethi, Kris Bieker, Olivia Uitto, Sarah Bock, Liz Doyon, Christina Lewis, Christie Bitter, Daniel Karelitz, Matthew Dunay, Robert Crawford, Katie Hand, Caroline Bullerjahn and Ettore Santucci, with invaluable assistance from Nathan Needle and Anastassia Korin.